Matthias Goebeler Selected Research

Pseudolymphoma

5/2021	EBER in situ hybridization in subcutaneous aluminum granulomas/lymphoid hyperplasia: A diagnostic clue to differentiate injection-associated lymphoid hyperplasia from other forms of pseudolymphomas and cutaneous lymphomas.
11/2013	Microvessel density and expression of vascular endothelial growth factor and its receptors in different subtypes of primary cutaneous B-cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthias Goebeler Research Topics

Disease

18	Melanoma (Melanoma, Malignant) 05/2022 - 08/2002
18	Neoplasms (Cancer) 05/2022 - 10/2013
9	Pemphigus (Pemphigus Vulgaris) 01/2022 - 01/2004
8	Bullous Pemphigoid (Pemphigoid) 01/2022 - 09/2005
8	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021 - 09/2011
7	Hypersensitivity (Allergy) 11/2018 - 03/2007
6	Lymphoma (Lymphomas) 05/2021 - 11/2013
5	Infections 01/2022 - 01/2014
5	Inflammation (Inflammations) 01/2021 - 07/2015
5	Contact Dermatitis (Eczema, Contact) 01/2016 - 03/2007
4	Wounds and Injuries (Trauma) 01/2022 - 10/2016
4	Merkel Cell Carcinoma 07/2021 - 04/2014
4	Exanthema (Rash) 02/2019 - 02/2003
4	Skin Diseases (Skin Disease) 01/2017 - 09/2004
3	Uveal melanoma 06/2021 - 10/2013
3	Bacterial Infections (Bacterial Infection) 12/2020 - 10/2016
3	Neoplasm Metastasis (Metastasis) 01/2019 - 08/2002
3	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2019 - 11/2012
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 11/2013
2	Virus Diseases (Viral Diseases) 01/2022 - 01/2016
2	Pseudolymphoma 05/2021 - 11/2013
2	Carcinogenesis 01/2021 - 11/2019
2	Neutropenia 12/2020 - 10/2020
2	COVID-19 01/2020 - 01/2020
2	Anaphylaxis (Anaphylactic Shock) 11/2018 - 02/2003
2	Urticaria (Hives) 11/2018 - 02/2003
2	Disease Progression 01/2018 - 10/2013
2	Systemic Scleroderma (Systemic Sclerosis) 12/2016 - 01/2016
2	Allergic Contact Dermatitis 01/2016 - 07/2015
2	Multiple Sclerosis 07/2015 - 11/2005
2	Cutaneous Lupus Erythematosus 05/2015 - 10/2008
2	Vasculitis (Vasculitides) 02/2014 - 02/2003
2	Purpura 02/2014 - 09/2010
2	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 02/2008 - 02/2006
2	Hypoxia (Hypoxemia) 03/2007 - 08/2002
1	Pyogenic Granuloma 05/2022
1	Pemphigus and fogo selvagem 01/2022
1	Mycosis Fungoides 01/2022
1	Kaposi Sarcoma (Kaposi's Sarcoma) 11/2021
1	Hemangiosarcoma (Angiosarcoma) 11/2021
1	Hemangioma (Angioma) 11/2021
1	Vascular Neoplasms (Neoplasms, Vascular) 11/2021
1	Skin Neoplasms (Skin Cancer) 10/2021
1	Hyperplasia 05/2021
1	Granuloma 05/2021

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2002
7	Immune Checkpoint InhibitorsIBA 10/2020 - 01/2018
6	Rituximab (Mabthera)FDA Link 10/2020 - 02/2006
5	AutoantibodiesIBA 01/2022 - 01/2004
5	Messenger RNA (mRNA)IBA 01/2022 - 08/2002
4	CytokinesIBA 01/2021 - 12/2016
4	NickelIBA 10/2011 - 03/2007
3	AntigensIBA 05/2022 - 07/2012
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 08/2002
3	Immunoglobulin G (IgG)IBA 01/2022 - 01/2017
3	NivolumabIBA 07/2021 - 08/2019
3	InterleukinsIBA 01/2021 - 01/2016
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2020 - 02/2019
3	pembrolizumabIBA 12/2019 - 11/2017
3	ParaffinIBA 01/2016 - 11/2013
3	HaptensIBA 01/2016 - 10/2011
3	AllergensIBA 07/2015 - 03/2007
2	Mitogen-Activated Protein KinasesIBA 05/2022 - 08/2002
2	VaccinesIBA 01/2022 - 02/2003
2	DesmogleinsIBA 01/2022 - 01/2017
2	KalininIBA 01/2022 - 01/2006
2	Biomarkers (Surrogate Marker)IBA 10/2021 - 07/2015
2	IpilimumabIBA 07/2021 - 12/2019
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2019
2	tyrosine receptor (receptor, tyrosine)IBA 01/2021 - 01/2019
2	Interleukin-17 (Interleukin 17)IBA 01/2021 - 01/2016
2	Oncogene Proteins (Oncogene Protein)IBA 01/2021 - 11/2019
2	Intravenous Immunoglobulins (IVIG)FDA Link 12/2020 - 01/2004
2	Biological ProductsIBA 02/2020 - 10/2019
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 09/2009
2	Immunoglobulins (Immunoglobulin)IBA 02/2019 - 11/2018
2	Immunoglobulin E (IgE)IBA 11/2018 - 03/2014
2	Diphosphonates (Bisphosphonates)IBA 01/2018 - 01/2016
2	Immunoglobulin A (IgA)IBA 11/2017 - 12/2013
2	Imiquimod (Aldara)FDA LinkGeneric 01/2016 - 01/2016
2	Interleukin-10 (Interleukin 10)IBA 01/2016 - 01/2016
2	FumaratesIBA 07/2015 - 07/2015
2	MetalsIBA 07/2015 - 10/2011
2	Toll-Like Receptor 4IBA 10/2011 - 09/2010
2	Dapsone FDA Link 09/2010 - 09/2005
2	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2009 - 01/2004
2	NF-kappa B (NF-kB)IBA 03/2007 - 08/2002
2	ChemokinesIBA 11/2005 - 10/2003
1	Brentuximab VedotinIBA 01/2022
1	AutoantigensIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022
1	Prednisone (Sone)FDA LinkGeneric 01/2022
1	Connexin 43 (Connexin43)IBA 11/2021
1	Keratin-15 (Keratin 15)IBA 10/2021
1	avelumabIBA 07/2021

Therapy/Procedure

22	Therapeutics 05/2022 - 01/2004
4	Immunotherapy 12/2020 - 01/2018
2	Injections 11/2018 - 11/2005
1	Aftercare (After-Treatment) 06/2021